Paolo Tarantino shared a post on X:
”Wonderful ENA Symposium 2024 keynote lecture on immunotherapy and microbiome by Jennifer Wargo.
The 1st neoadjuvant immunotherapy topic in the next 5 years: more cures, less surgery!
(And, hopefully, less toxicities too).”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
